Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec 22;185(26):4866-4869.
doi: 10.1016/j.cell.2022.12.003.

Relatlimab and nivolumab in the treatment of melanoma

Lewis Au  1 , James Larkin  2 , Samra Turajlic  3
Affiliations
Free article
Comment

Relatlimab and nivolumab in the treatment of melanoma

Lewis Au et al. Cell. .
Free article

Abstract

Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.L. reports - Honoraria: Bristol Myers Squibb, Pfizer, Novartis, Incyte, Merck Serono, Eisai, touchlME, touchEXPERTS, Royal College of Physicians, Cambridge Healthcare research, RCGP, VJOncology, Agence; Consulting or Advisory Role: Bristol Myers Squibb, Incyte, iOnctura, Apple Tree Partners, Merck Serono, Eisai, Debiopharm Group, Pierre Fabre, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude Health, AstraZeneca, GlaxoSmithKline, Calithera Biosciences, Ultimovacs, Seattle Genetics, eCancer, Insel Gruppe, Pfizer, Goldman Sachs, MSD Oncology, Agence; Research Funding: Pfizer (Inst), Novartis (Inst), MSD Recipient (Inst), Bristol Myers Squibb (Inst), Achilles Therapeutics (Inst), Roche (Inst), Nektar (Inst), Covance (Inst), Immunocore (Inst), AVEO (Inst), Pharmacyclics (Inst); Travel, Accommodations, Expenses: Roche/Genentech, GlaxoSmithKline, Pierre Fabre. S.T. reports - Financial support: Cancer Research UK, The Royal Marsden Cancer Charity, The Rosetrees Trust, Ventana Medical Systems Inc., National Institutes of Health, Melanoma Research Alliance, Roche that includes: speaking and lecture fees, Astra Zeneca that includes: speaking and lecture fees, Novartis that includes: speaking and lecture fees, Ipsen that includes: speaking and lecture fees; Patent “Indel mutations as a therapeutic target and predictive biomarker” (PCTGB2018/051,892) and (PCTGB2018/051,893) pending to EPO, and patent “Clear Cell Renal Cell Carcinoma Biomarkers” (P113326GB) pending to EPO.

Comment on

  • Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
  • Neoadjuvant relatlimab and nivolumab in resectable melanoma.
    Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Nature. 2022 Nov;611(7934):155-160. doi: 10.1038/s41586-022-05368-8. Epub 2022 Oct 26. Nature. 2022. PMID: 36289334 Free PMC article. Clinical Trial.

LinkOut - more resources